Who founded Mitotherapeutix LLC?

Mitotherapeutix LLC was founded by Mercedes Rincon in 2014.

Who are Mitotherapeutix LLC's investors?

Mitotherapeutix LLC's investors include Connecticut Innovations.

How much funding has Mitotherapeutix LLC raised?

Mitotherapeutix LLC has disclosed $3M raised across 2 rounds.

Where is Mitotherapeutix LLC headquartered?

Mitotherapeutix LLC is headquartered in Woodbridge, US.

Mitotherapeutix LLC

Woodbridge, US · Founded 2014 · Delaware LLC · 1 known investors

Find your way into Mitotherapeutix LLC

186 people in our graph share verified history with the Mitotherapeutix LLC team — schools, employers, funds. One of them is your warm intro.

Russ Nashunlockedknows Jack Talley · together at University of Connecticut (overlapped)

×11knows the team · via University of Connecticut

Mitotherapeutix develops siRNA-based drugs using RNA silencing to target disease-related genes, with an initial focus on a protein that regulates mitochondrial metabolic activity. The company aims to create therapies that treat a range of diseases by controlling this metabolic regulator.

Biotech Deep Tech

Founders & leadership

Mitotherapeutix LLC was founded in 2014 by Mercedes Rincon.

Mercedes RinconScientific Founder

Robert HemleyCo-Founder & COO

Robert HennesseyCo-Founder & Chairman of Board

Jack Talley inInterim CEOJack Talley is an interim CEO with over 30 years of pharmaceutical and biotechnology industry experience, including roles leading multiple public companies and directing clinical development programs from early stages through regulatory submissions to the FDA and EMA. He has deep expertise in oncology, hematology, metabolic disease, and CNS therapeutics, with particular experience in RNAi technology platforms and manufacturing compliance.

Cynthia Arbeeny inCSOCynthia Arbeeny is Chief Scientific Officer of Mitotherapeutix, a biopharmaceutical company developing RNA-based therapeutics for metabolic diseases. She brings extensive experience in drug discovery and development across pharmaceutical, biotechnology, and academic settings, with deep expertise in metabolic disease areas including diabetes, obesity, and kidney disease.

Board

Fenel EloiBoard director

Daniel WagnerBoard director

Investors · 1

Connecticut InnovationsNew Haven · $500K – $2M

Reported raises · per SEC filings

Form D private placements

$3M disclosed across 2 rounds · 2016–2017

▶$3MraisedMay 2025 · 5 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Fenel EloiDirector
Robert HemleyExecutive Officer, Director
Robert HennesseyExecutive Officer, Director
John V. TalleyExecutive Officer, Director
Daniel WagnerDirector

Offering amount: $3M
Amount sold: $3M
First sale: Dec 2017
Incorporated: Limited Liability Company, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$30KraisedOct 2016 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Robert HemleyExecutive Officer, Director
John TalleyExecutive Officer, Director
Robert HennesseyExecutive Officer, Director

Offering amount: $30K
Amount sold: $30K
First sale: Sep 2016
Incorporated: Limited Liability Company, Delaware, 2014
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

MitoRx Therapeutics5 shared keywordsMitoRx is a preclinical-stage biotech developing MTRX31, a first-in-class small molecule that restores mitochondrial metabolism to eliminate ectopic fat in patients with metabolically unhealthy, high-risk obesity. Rather than suppressing appetite, its approach aims to deliver durable weight loss and reduce risks of type 2 diabetes, MASH, and cardiovascular disease.

Mitrix4 shared keywordsMitrix Bio develops bioreactor-grown young mitochondria encased in extracellular vesicles ("Mitlets") intended for transplantation to supplement aging cells. The company targets mitochondrial dysfunction implicated in age-related diseases such as Alzheimer's, retinal disease, liver dysfunction, and immune senescence.

Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Mitotherapeutix LLC for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Mitotherapeutix LLC do?: Mitotherapeutix develops siRNA-based drugs using RNA silencing to target disease-related genes, with an initial focus on a protein that regulates mitochondrial metabolic activity. The company aims to create therapies that treat a range of diseases by controlling this metabolic regulator.
Who founded Mitotherapeutix LLC?: Mitotherapeutix LLC was founded by Mercedes Rincon in 2014.
Who are Mitotherapeutix LLC's investors?: Mitotherapeutix LLC's investors include Connecticut Innovations.
How much funding has Mitotherapeutix LLC raised?: Mitotherapeutix LLC has disclosed $3M raised across 2 rounds.
Where is Mitotherapeutix LLC headquartered?: Mitotherapeutix LLC is headquartered in Woodbridge, US.